A 3-week pause versus continued Bruton tyrosine kinase inhibitor use during COVID-19 vaccination in individuals with chronic lymphocytic leukaemia (IMPROVE trial): a randomised, open-label, superiority trial.
Cook JA, Patten PEM, Peckham N, Moss P, Phillips N, Abhishek A, Roberts T, Hodges M, Talbot G, Barber V, Francis A, Shields AM, Duley L, Hoogeboom R, Willett BJ, Scott S, Parry-Jones N, Eyre TA, Plested G, Vandici G, Wandroo FA, Hutchinson C, Paneesha S, Murray DJ, Martinez-Calle N, Jenkins S, Heartin E, Parry HM.
Cook JA, et al. Among authors: moss p.
Lancet Haematol. 2025 Apr;12(4):e294-e303. doi: 10.1016/S2352-3026(25)00008-0.
Lancet Haematol. 2025.
PMID: 40175001
Free article.
Clinical Trial.